| SC 13G/A | 2020-02-12 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 4,853,159 | 8.4% | EDGAR |
| SC 13G/A | 2020-02-07 | FMR LLC | Ultragenyx Pharmaceutical Inc. | 1,824,565 | 3.2% | EDGAR |
| SC 13G/A | 2020-02-06 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 4,733,084 | 8.2% | EDGAR |
| SC 13G/A | 2020-01-08 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 1,284,110 | 2.2% | EDGAR |
| SC 13G/A | 2019-10-10 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 3,259,962 | 5.6% | EDGAR |
| SC 13D | 2019-06-26 | Ultragenyx Pharmaceutical Inc. | Arcturus Therapeutics Holdings Inc. | 2,678,036 | 20.0% | EDGAR |
| SC 13G/A | 2019-02-15 | NEW PERSPECTIVE FUND | Ultragenyx Pharmaceutical Inc. | 2,768,288 | 5.4% | EDGAR |
| SC 13G/A | 2019-02-14 | Capital Research Global Investors | Ultragenyx Pharmaceutical Inc. | 5,856,155 | 11.5% | EDGAR |
| SC 13G/A | 2019-02-14 | Capital International Investors | Ultragenyx Pharmaceutical Inc. | 5,302,587 | 10.4% | EDGAR |
| SC 13G | 2019-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Ultragenyx Pharmaceutical Inc. | 2,730,381 | 5.3% | EDGAR |
| SC 13G/A | 2019-02-13 | FMR LLC | Ultragenyx Pharmaceutical Inc. | 2,949,186 | 5.8% | EDGAR |
| SC 13G/A | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 5,996,082 | 11.8% | EDGAR |
| SC 13G/A | 2019-02-11 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 4,161,780 | 8.2% | EDGAR |
| SC 13G/A | 2019-02-06 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 4,476,812 | 8.9% | EDGAR |
| SC 13G/A | 2018-02-14 | Capital Research Global Investors | Ultragenyx Pharmaceutical Inc. | 4,985,005 | 11.7% | EDGAR |
| SC 13G | 2018-02-14 | NEW PERSPECTIVE FUND | Ultragenyx Pharmaceutical Inc. | 2,768,288 | 6.5% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Ultragenyx Pharmaceutical Inc. | 3,648,275 | 8.6% | EDGAR |
| SC 13G/A | 2018-02-09 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 3,166,465 | 7.4% | EDGAR |
| SC 13G/A | 2018-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 5,859,120 | 13.8% | EDGAR |
| SC 13G/A | 2018-01-23 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 3,731,887 | 8.8% | EDGAR |